首页> 外文期刊>Neuropsychiatric Disease and Treatment >A preliminary assessment of a combination of rhodiola and saffron in the management of mild–moderate depression
【24h】

A preliminary assessment of a combination of rhodiola and saffron in the management of mild–moderate depression

机译:对红景天和藏红花联合治疗轻度-中度抑郁症的初步评估

获取原文
           

摘要

Objective: The medicinal plants Rhodiola rosea L. (rhodiola, golden root) and Crocus sativus L. (saffron) have been shown separately to induce significant effects in depression. The objective of this study was to assess a fixed combination of rhodiola and saffron in mild–moderate depression. Methods: In this observational study conducted with general practitioners (GPs), 45 adults (aged 18–85 years) suffering from mild or moderate depression (International Statistical Classification of Diseases and Related Health Problems 10th Revision definition) and reaching a score on the Hamilton Rating Scale for Depression of 8–18 were supplemented with a combination of rhodiola and saffron extracts (one tablet, 154 mg of rhodiola and 15 mg of saffron; recommended dose two tablets per day for 6 weeks). Results: After 6 weeks (D42) of supplementation, Hamilton Rating Scale for Depression scores (primary outcome) decreased significantly by 58%±28.5% (from 13.6±2.3 at D0 to 5.6±3.8 at D42, P 0.0001; n=41). Score improvement was reported in 85.4% of patients. A significant drop in both Hospital Anxiety and Depression Scale anxiety and depression scores was also observed at D42, the decrease being significant from 2 weeks of supplementation. At the end of the study, both GPs and patients deemed there was a significant improvement in depression (Clinical Global Impression – improvement and Patient Global Impression of Change). Safety was excellent, and no serious adverse effects were recorded. Conclusion: Results of this observational study performed in primary care suggest that the combination of rhodiola and saffron tested could be useful for the management of mild–moderate depression and improve depressive and anxiety symptoms. A double-blind placebo-controlled study is needed to confirm these results.
机译:目的:已证明药用植物红景天(Rhodiola rosea L.)和番红花番红花(番红花)分别对抑郁症具有明显的诱导作用。这项研究的目的是评估在轻度-中度抑郁症中红景天和藏红花的固定组合。方法:在这项由全科医生(GPs)进行的观察性研究中,有45位成年人(年龄在18-85岁之间)患有轻度或中度抑郁(《疾病和相关健康问题国际统计学分类》第10版修订版)并且得分达到汉密尔顿抑郁评分量表(8-18)补充了红景天和藏红花提取物的组合(1片,154毫克的红景天和15毫克的藏红花;建议剂量为两片,每天服用6周)。结果:补充6周(D42)后,汉密尔顿抑郁量表评分(主要结局)显着下降58%±28.5%(从D0的13.6±2.3降至D42的5.6±3.8,P <0.0001; n = 41 )。据报道,有85.4%的患者得分提高。在第42天,还观察到了医院焦虑和抑郁量表焦虑和抑郁评分的显着下降,从补充2周开始下降显着。在研究结束时,全科医生和患者均认为抑郁症有显着改善(临床总体印象–改善和患者总体印象改变)。安全性极好,未记录到严重的不良影响。结论:这项在基层医疗中进行的观察性研究结果表明,经测试的红景天和藏红花的组合可用于治疗轻度-中度抑郁症并改善抑郁和焦虑症状。需要双盲安慰剂对照研究来证实这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号